Literature DB >> 15676120

The Therapy of Lyme Neuroborreliosis.

Andrew R Pachner1.   

Abstract

The challenge for the neurologist in the treatment of Lyme neuroborreliosis is not in the treatment per se, but in the diagnosis. Neurological manifestations of Lyme disease can present in many forms, and diagnostic techniques which detect the spirochete directly; the culture or polymerase chain reaction of the spirochete in cerebrospinal fluid, are of disappointingly low yield. Therefore, the diagnosis is frequently not easy. After the diagnosis is made, antibiotic therapy is straightforward; Lyme neuroborreliosis should be treated with at least 2 weeks of antibiotics. In the United States, intravenous therapy with ceftriaxone or penicillin for 2 weeks is the standard, whereas in Europe oral doxycycline therapy is commonly administered. Either is effective, and my choice of therapy generally depends on the patient. Many patients have symptoms which continue after antibiotic therapy referable to persistent inflammation, and, for those patients, I will commonly prescribe nonsteroidal anti-inflammatory medications.

Entities:  

Year:  2005        PMID: 15676120     DOI: 10.1007/s11940-005-0026-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  18 in total

Review 1.  The rhesus model of Lyme neuroborreliosis.

Authors:  A R Pachner; H Gelderblom; D Cadavid
Journal:  Immunol Rev       Date:  2001-10       Impact factor: 12.988

2.  Facial paralysis in Lyme disease.

Authors:  J R Clark; R D Carlson; C T Sasaki; A R Pachner; A C Steere
Journal:  Laryngoscope       Date:  1985-11       Impact factor: 3.325

3.  Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis.

Authors:  M Karlsson; S Hammers-Berggren; L Lindquist; G Stiernstedt; B Svenungsson
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

4.  Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group.

Authors:  M A Gerber; E D Shapiro; G S Burke; V J Parcells; G L Bell
Journal:  N Engl J Med       Date:  1996-10-24       Impact factor: 91.245

5.  Genotype determines phenotype in experimental Lyme borreliosis.

Authors:  Andrew R Pachner; Donna Dail; Yunhong Bai; Marie Sondey; Lena Pak; Kavitha Narayan; Diego Cadavid
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

6.  Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain.

Authors:  H Reiber; P Lange
Journal:  Clin Chem       Date:  1991-07       Impact factor: 8.327

Review 7.  Pseudotumor cerebri in Lyme disease: a case report and literature review.

Authors:  L Kan; S K Sood; J Maytal
Journal:  Pediatr Neurol       Date:  1998-05       Impact factor: 3.372

8.  Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.

Authors:  M Karlsson; K Hovind-Hougen; B Svenungsson; G Stiernstedt
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

9.  Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Authors:  A C Steere; A R Pachner; S E Malawista
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

10.  The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis.

Authors:  A R Pachner; A C Steere
Journal:  Neurology       Date:  1985-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.